The abstract is read at the publisher; the summary is JClub's.
In the NEO-CESQ phase II trial of perioperative cemiplimab for stage III–IV resectable cutaneous squamous cell carcinoma, major pathological response occurred in 11 of 25 patients (44%).
- Why it matters: Biomarkers that predict pathological response and recurrence in high-risk resectable CSCC are not established, limiting patient selection for perioperative programmed death 1 blockade.
- What they did: Patients received neoadjuvant cemiplimab, surgery, then adjuvant treatment; investigators assessed major pathological response (<10% viable tumor) and linked it to survival using hazard ratios, alongside tumor NanoString PanCancer IO 360 transcriptomics and longitudinal serum cytokines.
- The result: An exploratory 10-gene NeoSquamos classifier predicted recurrence-free survival with an AUC of 0.838, and interferon-γ-related signatures were enriched in responders while non-responders showed higher WNT5A and CD276 expression.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.